Drug Approval | June 01, 2026
Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial
The therapy also delivered significant improvements in key liver enzyme markers
The therapy also delivered significant improvements in key liver enzyme markers
Derived from rice bran wax, Licocare RBW products offer a renewable solution with a substantially lower carbon footprint than conventional montan waxes
The approval marks a major milestone in the global fight against antimicrobial resistance
Crucially, Lupin is the exclusive first-to-file applicant for this product and is eligible for 180-day generic drug exclusivity in the U.S. market
The filing is backed by results from the pivotal SERENA-6 Phase III trial
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
The Establishment Inspection Report came following closure of a product- specific pre-approval inspection from March 2 to March 7, 2026
Clearance marks major shift beyond chemotherapy
The development comes as stroke remains one of the world’s biggest health threats
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
Subscribe To Our Newsletter & Stay Updated
